Literature DB >> 22456618

The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression.

Francesca Schiavi1, Serena Demattè, Maria Enrica Cecchini, Elisa Taschin, Sara Bobisse, Antonella Del Piano, Davide Donner, Mattia Barbareschi, Vittorio Manera, Stefania Zovato, Zoran Erlic, Theodoros Savvoukidis, Susi Barollo, Franco Grego, Franco Trabalzini, Pietro Amistà, Cesare Grandi, Fabio Branz, Fabio Marroni, Hartmut P H Neumann, Giuseppe Opocher.   

Abstract

CONTEXT: Anecdotal evidence suggests a high incidence in Trentino, Italy, of head and neck paragangliomas (HNPGL), a rare autosomal dominant disease called paraganglioma type 1 syndrome and caused by germ-line mutations of the SDHD gene.
OBJECTIVE: The aim of this study was to investigate the origin, spread, and clinical expression of the disease in this geographic region. DESIGN, SETTING, AND PARTICIPANTS: Trentino natives with HNPGL were recruited for establishing clinical expression of the disease, presence of a founder effect, and age of common ancestor. A large sample of the local population was recruited for determination of mutation prevalence and spread. MAIN OUTCOME MEASURES: SDHD genetic testing was offered to first-degree relatives, and clinical surveillance was offered to at-risk carriers. The hypothesis of a founder effect was explored by haplotype analysis, and time to the most recent common ancestor was estimated by decay of haplotype sharing over time.
RESULTS: A total of 287 of the 540 recruited individuals from 95 kindreds carried the SDHD c.341A>G p.Tyr114Cys mutation. The prevalent phenotype was bilateral or multiple HNPGL, with low prevalence of pheochromocytoma and malignant forms. Penetrance was high. A common ancestor was dated between the 14th and 15th century, with the mutation spreading from the Mocheni Valley, a geographic, cultural and, presumably, a genetic isolate to 1.5% of the region's population.
CONCLUSIONS: A combination of particular demographic, geographical, and historical conditions has resulted in the oldest and largest SDHD founder effect so far characterized and has transformed a rare disease into an endemic disease with major public health implications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22456618     DOI: 10.1210/jc.2011-2597

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Surgical management of carotid body tumors: a 15-year single institution experience employing an interdisciplinary approach.

Authors:  Jennifer L Dixon; Marvin D Atkins; William T Bohannon; Clifford J Buckley; Terry C Lairmore
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-01

2.  A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.

Authors:  A Guha; Z Musil; A Vicha; T Zelinka; K Pacak; J Astl; M Chovanec
Journal:  Neoplasma       Date:  2019-06-29       Impact factor: 2.575

Review 3.  Hypothesis: Why Different Types of SDH Gene Variants Cause Divergent Tumor Phenotypes.

Authors:  Jean-Pierre Bayley; Peter Devilee
Journal:  Genes (Basel)       Date:  2022-06-07       Impact factor: 4.141

4.  Role of ultrasound and color Doppler imaging in the detection of carotid paragangliomas.

Authors:  S Demattè; D Di Sarra; F Schiavi; A Casadei; G Opocher
Journal:  J Ultrasound       Date:  2012-05-30

5.  Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers.

Authors:  Berdine L Heesterman; Lisa M H de Pont; Andel Gl van der Mey; Jean-Pierre Bayley; Eleonora Pm Corssmit; Frederik J Hes; Berit M Verbist; Peter Paul G van Benthem; Jeroen C Jansen
Journal:  Eur J Hum Genet       Date:  2018-05-18       Impact factor: 4.246

Review 6.  International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers.

Authors:  Laurence Amar; Karel Pacak; Olivier Steichen; Scott A Akker; Simon J B Aylwin; Eric Baudin; Alexandre Buffet; Nelly Burnichon; Roderick J Clifton-Bligh; Patricia L M Dahia; Martin Fassnacht; Ashley B Grossman; Philippe Herman; Rodney J Hicks; Andrzej Januszewicz; Camilo Jimenez; Henricus P M Kunst; Dylan Lewis; Massimo Mannelli; Mitsuhide Naruse; Mercedes Robledo; David Taïeb; David R Taylor; Henri J L M Timmers; Giorgio Treglia; Nicola Tufton; William F Young; Jacques W M Lenders; Anne-Paule Gimenez-Roqueplo; Charlotte Lussey-Lepoutre
Journal:  Nat Rev Endocrinol       Date:  2021-05-21       Impact factor: 43.330

7.  Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish pheochromocytoma/paraganglioma patients.

Authors:  Marc Bennedbæk; Maria Rossing; Åse K Rasmussen; Anne-Marie Gerdes; Anne-Bine Skytte; Uffe B Jensen; Finn C Nielsen; Thomas V O Hansen
Journal:  Hered Cancer Clin Pract       Date:  2016-06-08       Impact factor: 2.857

Review 8.  A differential diagnosis of inherited endocrine tumors and their tumor counterparts.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Rodrigo A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

Review 9.  Paragangliomas/Pheochromocytomas: clinically oriented genetic testing.

Authors:  Rute Martins; Maria João Bugalho
Journal:  Int J Endocrinol       Date:  2014-05-12       Impact factor: 3.257

10.  Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland.

Authors:  Serban Radian; Yoan Diekmann; Plamena Gabrovska; Brendan Holland; Lisa Bradley; Helen Wallace; Karen Stals; Anna-Marie Bussell; Karen McGurren; Martin Cuesta; Anthony W Ryan; Maria Herincs; Laura C Hernández-Ramírez; Aidan Holland; Jade Samuels; Elena Daniela Aflorei; Sayka Barry; Judit Dénes; Ida Pernicova; Craig E Stiles; Giampaolo Trivellin; Ronan McCloskey; Michal Ajzensztejn; Noina Abid; Scott A Akker; Moises Mercado; Mark Cohen; Rajesh V Thakker; Stephanie Baldeweg; Ariel Barkan; Madalina Musat; Miles Levy; Stephen M Orme; Martina Unterländer; Joachim Burger; Ajith V Kumar; Sian Ellard; Joseph McPartlin; Ross McManus; Gerard J Linden; Brew Atkinson; David J Balding; Amar Agha; Chris J Thompson; Steven J Hunter; Mark G Thomas; Patrick J Morrison; Márta Korbonits
Journal:  Hum Mutat       Date:  2016-10-04       Impact factor: 4.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.